Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Transfusion-associated graft-versus-host disease (TA-GVHD) and graft-versus-host disease (GVHD): Pathophysiology and management (contrasted and compared).
Valsami S, Dryllis G, Papanastasi K, Kokoris S, Kriebardis A, Nikitiadis K, Konstantopoulos K, Politou M. Valsami S, et al. Among authors: dryllis g. Hematol Oncol Stem Cell Ther. 2024 Oct-Dec 01;17(4):203-210. doi: 10.4103/hemoncstem.HEMONCSTEM-D-24-00043. Epub 2025 Jan 20. Hematol Oncol Stem Cell Ther. 2024. PMID: 39829094 Free article. Review.
The Clinical and Prognostic Significance of Ribonucleotide Reductase Subunits RRM1 and RRM2 mRNA Levels in Patients with Chronic Lymphocytic Leukemia.
Chatzidavid S, Kontandreopoulou CN, Diamantopoulos PT, Giannakopoulou N, Katsiampoura P, Stafylidis C, Dryllis G, Kyrtsonis MC, Dimou M, Panayiotidis P, Viniou NA. Chatzidavid S, et al. Among authors: dryllis g. Clin Hematol Int. 2023 Jun;5(2-3):92-100. doi: 10.1007/s44228-023-00033-x. Epub 2023 Feb 22. Clin Hematol Int. 2023. PMID: 36811764 Free PMC article.
Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine.
Kontandreopoulou CN, Diamantopoulos PT, Giannopoulos A, Symeonidis A, Kotsianidis I, Pappa V, Galanopoulos A, Panayiotidis P, Dimou M, Solomou E, Loupis T, Zoi K, Giannakopoulou N, Dryllis G, Hatzidavid S, Viniou NA; Hellenic MDS study Group. Kontandreopoulou CN, et al. Among authors: dryllis g. Leuk Lymphoma. 2022 Mar;63(3):729-737. doi: 10.1080/10428194.2021.1998484. Epub 2021 Nov 5. Leuk Lymphoma. 2022. PMID: 34738857
The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes.
Diamantopoulos PT, Symeonidis A, Pappa V, Kotsianidis I, Galanopoulos A, Pontikoglou C, Anagnostopoulos A, Vassilopoulos G, Zikos P, Hatzimichael E, Papaioannou M, Megalakaki A, Repousis P, Kotsopoulou M, Dimou M, Solomou E, Dryllis G, Tsokanas D, Papoutselis MK, Papageorgiou S, Kyrtshonis MC, Kourakli A, Papadaki H, Panayiotidis P, Viniou NA. Diamantopoulos PT, et al. Among authors: dryllis g. Br J Haematol. 2021 Mar;192(6):978-987. doi: 10.1111/bjh.17062. Epub 2020 Aug 30. Br J Haematol. 2021. PMID: 32862447 Free article.
Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.
Papadopoulos V, Diamantopoulos PT, Papageorgiou SG, Papoutselis M, Vrachiolias G, Pappa V, Galanopoulos AG, Vassilakopoulos TP, Hatzimichael E, Zikos P, Papadaki HA, Bouchla A, Panayiotidis P, Megalakaki A, Papaioannou M, Liapis K, Dryllis G, Tsokanas D, Kourakli A, Symeonidis A, Viniou NA, Kotsianidis I. Papadopoulos V, et al. Among authors: dryllis g. Hematol Oncol. 2020 Oct;38(4):541-553. doi: 10.1002/hon.2756. Epub 2020 Jun 26. Hematol Oncol. 2020. PMID: 32495951
37 results